Immunoassay News and Research

RSS

Polymedco's automated immunoassay fecal occult blood test system receives FDA clearance

Polymedco, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the OC-Sensor Diana, a high throughput automated system for the immunoassay fecal occult blood test (FIT) used for detecting gastrointestinal bleeding associated with disorders such as colorectal cancer, polyps and colitis.

5 Feb 2010

NanoInk launches configured protein array kit from its Nano BioDiscovery Division

NanoInk, Inc.®, a global leader in nanotechnology, is pleased to announce the launch of its first completely configured protein array kit from its Nano BioDiscovery™ Division. Based on the patented Dip Pen Nanolithography® (DPN®) platform, NanoInk's fluorescent assays enable nanoscale detection of clinically relevant proteins.

2 Feb 2010

Agent-enhanced CT scan plays a supporting role in diagnosing severe cases of H1N1 flu virus

Published reports on the usefulness of CT scans for complicated H1N1 cases have spurred use of these procedures in U.S. hospitals. According to healthcare market research publisher Kalorama Information, this opens up a pathway of diagnostics for physicians and overall is a positive sign not only for the technology but also for companies making chemical agents for procedures.

29 Jan 2010

Intrinsic Bioprobes licenses diabetes biomarkers to Ortho-Clinical Diagnostics

Intrinsic Bioprobes today announced the exclusive licensing of two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, Inc. (Raritan, NJ). The biomarkers are modified forms of blood-circulating proteins and have been linked with the presence of pre-diabetes and type 2 diabetes. The financial terms of the licensing agreement were not disclosed.

From Ortho-Clinical Diagnostics, Inc. 22 Jan 2010

European approval for Abbott's new ovarian cancer diagnostic test

A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynecological cancer.

14 Jan 2010

Jiangsu Government grants $1.8M for research and development of hUC-MSC technologies

The Jiangsu Government's Science and Technology Department has announced a $1.8 million grant - the Jiangsu Technological Achievements Transformational Grant - to support the research and development of human umbilical cord mesenchymal stem cell (hUC-MSC) technologies. The grant recipient and administrator, Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com ), is working with Jiangsu University and Nanjing University's Drum Tower Hospital to fulfill the grant's requirements.

9 Jan 2010

Sword Diagnostics receives patent on improved sensitivity technology for detection of biological organisms

Sword Diagnostics, Inc. is pleased to announce that the United States Patent Office (USPTO) has issued patent number 7,599,057 titled "Method and Apparatus for Detection of Biological Organisms using Raman Scattering" to the company.

15 Dec 2009

Merck Chimie advances to the next phase in commercializing Beads, reports CardioGenics Holdings

CardioGenics Holdings Inc., a developer of technology and products targeting the immunoassay segment of the IVD testing market, reports that Merck Chimie S.A.S. ("Merck Chimie") is progressing to the next phase of the commercialization of CardioGenics' proprietary silver coated paramagnetic Beads ("Beads").

25 Nov 2009

RBM and Covance sign biomarker alliance and services agreement

Rules-Based Medicine, Inc. (RBM) today announced it has entered into a biomarker alliance and services agreement with Covance Inc. that will provide biotechnology and pharmaceutical companies with a powerful combination of biomarker technologies and services for use in drug development. Under terms of the agreement, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and RBM shall use Covance as its exclusive referral source for laboratory testing services.

19 Nov 2009

USPTO issues patent number to Vermillion's biomarkers for detecting ovarian cancer

Vermillion, Inc., a molecular diagnostics company, today announced that the U.S. Patent Office (USPTO) has issued patent number 7,605,003 titled "Use of biomarkers for detecting ovarian cancer" to the Company for the discovery of biomarkers for ovarian cancer.

12 Nov 2009

eBioscience acquires privately held immunoassay technology pioneer Bender MedSystems

eBioscience Corporation today announced that it has acquired privately held immunoassay technology pioneer Bender MedSystems GmbH in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA® and FlowCytomix(TM) brands that target the life sciences and diagnostics markets.

27 Oct 2009

New Category I CPT code for AspirinWorks Test Kit

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today that a new Category I Current Procedural Terminology (CPT) code has been published by the American Medical Association (AMA) for the AspirinWorks Test Kit.

23 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

AABM Team wins two medals in a national contest

The Aquatic Animal Bio-Medicine R&D Team (AABM Team) of National Cheng Kung University (NCKU) in Taiwan, led by Distinguished Prof. Huey-Lang Yang from Institute of Biotechnology, won two medals out of more than 100 teams in the national contest, “2009 Crazy Idea – King of Practical Applications on Creative Researches and Development of Biotechnology,” organized by the Industrial Development Bureau of the Ministry of Economic Affairs, Taiwan.

25 Sep 2009

Aushon BioSystems completes construction of new laboratory and manufacturing facility

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announced today that it has completed the renovation and expansion of its Billerica, MA corporate headquarters.

10 Sep 2009

Cell Biosciences acquires Alpha Innotech for $17.9 million

Cell Biosciences, Inc. and Alpha Innotech Corp. today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for $1.50 per share, or approximately $17.9 million in cash.

9 Sep 2009

rPA anthrax vaccine and its Valortim anthrax anti-toxin program data presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.

4 Sep 2009

Thermo Fisher Scientific to acquire B.R.A.H.M.S. for $470 million

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement to acquire B.R.A.H.M.S. AG for €330 million (approximately $470 million USD). B.R.A.H.M.S. is a leading provider of specialty in-vitro diagnostic tests based on its patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.

From Thermo Fisher Scientific Inc. 3 Sep 2009

NAT gains importance as traditional testing methods become inadequate

An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).

28 Aug 2009

Nanofluidic biopsy detects subtle changes in cancer cells

By taking two standard laboratory techniques - capillary electrophoresis and antibody-based protein detection - and shrinking them to the nanoscale, researchers at the Stanford University School of Medicine have created a new method for detecting miniscule changes in the levels of proteins associated with cancer.

28 Jun 2009